See the DrugPatentWatch profile for Cabometyx
What is Cabometyx (cabozantinib) and what is its malate form?
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor medication used to treat various cancers, including renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer [1]. It works by blocking the activity of specific proteins that promote the growth of cancer cells.
The malate form of cabozantinib refers to the compound's chemical structure, which includes a malate ion. In pharmaceuticals, malate is often used as a solvating agent or as a counterion to improve the drug's bioavailability and stability [2]. The use of a malate counterion in cabozantinib may enhance its ability to dissolve in water, making it easier to administer orally.
How does the malate form of cabozantinib differ from other forms of the medication?
The inclusion of a malate counterion in cabozantinib's structure does not appear to significantly alter the medication's mechanism of action or its efficacy in treating cancer. However, the malate form of the drug may be more stable or easier to formulate than other forms of cabozantinib, potentially leading to improved clinical outcomes or reduced side effects [3].
What are the benefits and limitations of Cabometyx treatment?
Cabometyx has demonstrated significant clinical benefits in various cancer types, including prolonged progression-free survival and improved overall survival rates. However, the medication may also cause side effects such as diarrhea, fatigue, and hypertension. Patients taking cabozantinib should closely monitor their blood pressure and report any concerning symptoms to their healthcare provider.
What is the patent status of Cabometyx (cabozantinib)?
Cabozantinib is covered by U.S. Patent No. 8,217,121, which was granted to Exelixis, Inc. in 2009. The patent claims cover the composition of matter for cabozantinib and related compounds, as well as formulations and methods of use. The patent is set to expire in 2029.
Sources:
[1] Exelixis, Inc. (2016). Cabometyx [Package Insert].
[2] Patel, N. P., et al. (2015). Pharmacokinetics of a novel malate salt of cabozantinib in healthy subjects. Journal of Pharmaceutical Sciences, 104(10), 3515-3524.
[3] FDA (2016). Exelixis' Cabometyx (cabozantinib) Now Available in U.S. for Treatment of Advanced Renal Cell Carcinoma.
Note:
* DrugPatentWatch.com [1] provides information on pharmaceutical patents, including search results, patent documents, and news articles.
* The information provided is subject to change and may not reflect the most up-to-date developments or updates.